← All stocks

Spyre Therapeutics, Inc.

SYRE Scheduled selling only

CIK 0001636282 #969 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$436.71M

$19.58M on a plan · $417.13M straight out of an exercise

Sold at will

$0.00

0 of 79 sales

Net

−$436.71M

$0.00 against sales at will

By person

7 insiders · 79 transactions

74.2×

Cameron Turtle holds 74.2 times base salary in stock. $49.37M of shares against $665.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Cameron Turtle last reported holding, valued at $89.35, the price Common Stock was last bought or sold at on the open market here, on 2 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Fairmount Funds Management LLC entity

Director

—

$399.66M (1) scheduled

−$399.66M

0.0000%

$0.00

−100.0%

Turtle Cameron

Chief Executive Officer

—

$9.99M (34) scheduled

−$9.99M

552,540

0.6266%

$49.37M

−26.1%

HENDERSON MICHAEL THOMAS

Director

—

$7.95M (5) scheduled

−$7.95M

68,606

0.0778%

$6.13M

—

Sloan Sheldon

Chief Medical Officer

—

$7.35M (11) scheduled

−$7.35M

0.0000%

$0.00

—

Burrows Scott L

Chief Financial Officer

—

$6.86M (20) scheduled

−$6.86M

79,762

0.0905%

$7.13M

−31.5%

King-Jones Heidy

See Remarks

—

$2.48M (5) scheduled

−$2.48M

2,845

0.0032%

$254.20K

0.0%

Albers Jeffrey W.

Director

—

$2.40M (3) scheduled

−$2.40M

9,360

0.0106%

$836.32K

−72.8%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 39

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 2

Sales on a Rule 10b5-1 plan 40

Sales straight out of an exercise 39

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 933,764

History held since 16 Feb 2017